Protected: Functional Neuromodulation CEO: Deep Brain Stimulation the Next Step in Alzheimer’s Disease
There is no excerpt because this is a protected post.
News
Adherex Enrolls First Patient in Clinical Trial For Metastatic Breast Cancer
In 2010, NCI estimated that 207,090 women were diagnosed with breast cancer, while 39,840 women likely died from the disease.
Insituvue To Present X-Ray Technology At OneMedForum NY 2011
Insituvue is preparing to commercialize the Sonic Flashlight technology, a device developed at University of Pittsburgh that gives medical professionals a better view during procedures.
NeoStem’s Suzhou Erye Receives 2 Pharma Industry Awards, Positioned For Future Growth
NeoStem announced Tuesday that Chinese generic pharma company Suzhou Erye, in which it owns a 51% majority stake, has won two awards at the 2011 Chempharm Brand Summit.
Del Mar Pharmaceuticals Is Fighting Cancer One Molecule At A Time
Del Mar Pharmaceuticals was recently added to the roster of presenting companies at OneMedForum NY 2011.
MEDomics to Present At OneMedForum NY 2011
OneMedForum NY 2011 welcomes MEDomics, LLC, a molecular diagnostic laboratory, confirmed to present in June at the annual conference.
Aduro Biotech, OneMedForum SF Presenting Company, Announces $20 Million Financing
Aduro BioTech, a OneMedForum presenting company is engineering Listeria to treat Pancreatic Cancer and other infectious diseases.
New Software From iCAD Helps Doctors Diagnose Prostate Cancer
New software being used at Englewood Hospital and Medical Center should help detect prostate cancer earlier, eliminate unnecessary testing procedures and help form a treatment plan.
OneMedForum NY 2011 Grows Its Advisory Board And Selects Initial Presenters
OneMedForum NY 2011, to be held June 23 -24, has added new members to the Advisory Board and selected an initial group of “discovery” lesser known companies with terrific growth potential.
BiOptix Closes $9 Million Series B Funding
BiOptix, headquartered in Boulder, Colorado, seeks to expand the power of label-free technology with its groundbreaking Surface Plasmon-enhanced Common Path Interferometry (SPE) instrument, the ACCOLADE. […]